Sutro Biopharma (NASDAQ:STRO) Upgraded at Citizens Jmp

Citizens Jmp upgraded shares of Sutro Biopharma (NASDAQ:STRO) from a market perform rating to a market outperform rating in a research report released on Tuesday morning, Marketbeat reports. They currently have $23.00 price target on the stock.

A number of other research firms have also commented on STRO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Monday, December 22nd. HC Wainwright increased their target price on shares of Sutro Biopharma to $10.00 and gave the stock a “neutral” rating in a research report on Monday, December 22nd. Wedbush reaffirmed a “neutral” rating and set a $100.00 target price (up from $20.00) on shares of Sutro Biopharma in a report on Tuesday, December 2nd. Wall Street Zen downgraded shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Citigroup raised Sutro Biopharma to an “outperform” rating in a research report on Tuesday. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Sutro Biopharma presently has a consensus rating of “Hold” and an average target price of $31.83.

Sutro Biopharma Trading Up 3.3%

Shares of NASDAQ STRO opened at $16.32 on Tuesday. The firm has a market cap of $138.88 million, a P/E ratio of -0.63 and a beta of 1.52. The business’s 50 day moving average is $10.46 and its 200-day moving average is $9.45. Sutro Biopharma has a 1-year low of $5.23 and a 1-year high of $21.50.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.25). The firm had revenue of $9.69 million during the quarter, compared to analyst estimates of $10.14 million. Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. Analysts forecast that Sutro Biopharma will post -2.92 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Sutro Biopharma in the 2nd quarter valued at $27,000. Bridgeway Capital Management LLC raised its holdings in shares of Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after buying an additional 30,000 shares in the last quarter. Savant Capital LLC bought a new stake in shares of Sutro Biopharma during the 2nd quarter worth $37,000. CWM LLC lifted its position in shares of Sutro Biopharma by 73.2% during the 2nd quarter. CWM LLC now owns 56,657 shares of the company’s stock worth $40,000 after buying an additional 23,941 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in Sutro Biopharma by 174.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company’s stock valued at $43,000 after buying an additional 38,561 shares in the last quarter. 96.99% of the stock is currently owned by institutional investors and hedge funds.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.